ArticleFrontiers in public health2023
Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Budget Impact of Faricimab in Neovascular Age-Related Macular Degeneration in the Netherlands: A Systematic Review and Meta-Analysis of Injection Count.Ophthalmology and therapy · 2026Pooled it
- Efficacy and safety of intravitreal conbercept and triamcinolone acetonide for wet age-related macular degeneration in China: a meta-analysis.International ophthalmology · 2024Pooled it
- Murine models of neovascular AMD revisited: Mechanistic pathways, immune-metabolic crosstalk, and the impact of aging and sex.Experimental eye research · 2026Review
- Integrative Network Pharmacology Analysis of Gut Microbial Metabolite-Mediated Gut-Eye Axis Regulation in Major Blinding Retinal Diseases.Ophthalmology science · 2026Article
- Therapeutic Equivalence of Eyluxvi (Aflibercept) to Eylea in Neovascular Age-Related Macular Degeneration: ALTERA Trial (Randomized).Ophthalmology and therapy · 2026Article
- Decoding the Bone-Eye Axis: Machine Learning for Age-Related Macular Degeneration Risk Prediction.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- The global disease burden and associated risk factors of age-related macular degeneration: a comprehensive analysis.International ophthalmology · 2025Article
- Association between low handgrip strength and the increased risk of age-related macular degeneration: results from UK biobank cohort study.Aging clinical and experimental research · 2025Article
- Functional scaffolds design strategies for retinal repair and regeneration.Materials today. Bio · 2025Review
- Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Global, country, and regional cancer burden attributable to dietary risk: Results from the global burden of disease study 2021.BMC public health · 2025Article
- Associations between patient-reported vision impairment in low luminance and vision-related quality of life in intermediate age-related macular degeneration.Scientific reports · 2025Article
- Potential to improve the burden of age-related macular degeneration: results from the Global Burden of Disease Study 2021.Eye (London, England) · 2025Article
- The burden of age-related macular degeneration and its socioeconomic associates in the Eastern Mediterranean Region from 1990 to 2021.Scientific reports · 2025Article
- Burdens and trends of age-related macular degeneration at global, regional, and national levels,1990-2021: findings from the 2021 global burden of disease study.Eye (London, England) · 2025Article
- Looking beyond the eyes of the patient: The importance of effective communication in the treatment of age-related macular degeneration.Acta ophthalmologica · 2025Article
- Global trends and disparities in burden of blindness and vision loss caused by non-communicable diseases from 1990 to 2021, and forecasts to 2045: a systematic analysis for the global burden of disease study 2021.Frontiers in medicine · 2025Article
- Association Between C22:5-Containing Lipids and RPE Pathologies in Mice with Tmem135 Overexpression.Advances in experimental medicine and biology · 2025Article
- Global burden of age-related macular degeneration (1990-2021): trends, age-sex disparities, and socioeconomic dynamics from the GBD study.Frontiers in public health · 2025Article
- Impact of Dry Age-Related Macular Degeneration on Daily Activities and Quality of Life: Interview Findings From Patients and Caregivers Relative to a General Population.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to estimate the trends and disparities in the worldwide burden for health of AMD, overall and by age, sex, socio-demographic index (SDI), region, and nation using prevalence and years lived with disability (YLDs) from Global Burden of Disease (GBD) study 2019. Methods: This retrospective study presents the prevalent AMD cases and YLDs from 1990-2019, as well as the age-standardized prevalence rate (ASPR) and age-standardized YLD rate (ASYR) of AMD. To measure changes over time, estimated annual percentage changes (EAPCs) of the age-standardized rates (ASRs) were analyzed globally, then studied further by sex, SDI, region, and nation. We included data from the 2019 Global Burden of Disease (GBD) database to examine AMD prevalence and YLDs from 1990-2019 in 204 countries and territories, as well as demographic information such as age, sex, SDI, region, and nation. Results: Globally, the number of prevalent AMD cases increased from 3,581,329.17 (95% uncertainty interval [UI], 3,025,619.4-4,188,835.7) in 1990 to 7,792,530 (95% UI, 6,526,081.5-9,159,394.9) in 2019, and the number of YLDs increased from 296,771.93 (95% uncertainty interval [UI], 205,462.8-418,699.82) in 1990 to 564,055.1 (95% UI, 392,930.7-789,194.64) in 2019. The ASPR of AMD had a decreased trend with an EAPC of -0.15 (95% confidence interval [CI], -0.2 to -0.11) from 1990 to 2019, and the ASYR of AMD showed a decreased trend with an EAPC of -0.71 (95% confidence interval [CI], -0.78 to -0.65) during this period. The prevalence and YLDs of AMD in adults over 50 years of age showed a significant increase. The prevalence and YLDs of AMD were significantly higher in females than males, overall. The ASPRs and ASYRs in low SDI regions was greater than in high SDI regions from 1990 to 2019. In addition, increases in prevalence and YLDs differed by regions and nations, as well as level of socio-economic development. Conclusion: The number of prevalent cases and YLDs due to AMD increased over 30 years and were directly linked to age, sex, socio-economic status, and geographic location. These findings can not only guide public health work but also provide an epidemiological basis for global strategy formulation regarding this global health challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.